Note on nintedanib
In November 2021, NICE recommended nintedanib as a treatment option for chronic progressive fibrosing interstitial lung diseases. This group of diseases includes but is not limited to IIP, autoimmune ILD and hypersensitivity pneumonitis.
Take your subscriptions with you
Our mobile app allows you to access your interview and exam question banks wherever you are.